Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study

Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study

Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) acquired resistance was an inevitably events in NSCLC treatment. Aims Intending to overcome the acquired resistance of EGFR‐TKI. Materials & Methods A clinical trial was, we enrolled 12 patients who were s...

Full description

Bibliographic Details
Main Authors: Minghui Liu, Xin Li, Hongbing Zhang, Fan Ren, Jinghao Liu, Yongwen Li, Ming Dong, Honglin Zhao, Song Xu, Hongyu Liu, Jun Chen
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Cancer Medicine
Subjects:
apatinib
circulating tumor DNA
EGFR‐TKI
NSCLC
safety
Online Access:https://doi.org/10.1002/cam4.6737

Internet

https://doi.org/10.1002/cam4.6737

Similar Items